Graphene Investments SAS Grows Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Graphene Investments SAS boosted its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 22.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 15,000 shares of the medical research company’s stock after buying an additional 2,700 shares during the quarter. IQVIA makes up about 2.0% of Graphene Investments SAS’s investment portfolio, making the stock its 25th largest holding. Graphene Investments SAS’s holdings in IQVIA were worth $2,948,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in IQV. FMR LLC increased its stake in shares of IQVIA by 38.7% in the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after purchasing an additional 804,963 shares in the last quarter. JPMorgan Chase & Co. increased its position in IQVIA by 46.2% in the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after buying an additional 583,396 shares in the last quarter. Impax Asset Management Group plc lifted its position in shares of IQVIA by 9.7% during the 3rd quarter. Impax Asset Management Group plc now owns 1,793,010 shares of the medical research company’s stock valued at $423,885,000 after buying an additional 157,809 shares in the last quarter. Nordea Investment Management AB grew its stake in shares of IQVIA by 47.4% during the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock valued at $277,908,000 after acquiring an additional 452,029 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in IQVIA by 3.4% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,226,083 shares of the medical research company’s stock worth $290,545,000 after acquiring an additional 39,772 shares in the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. TD Cowen dropped their price target on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Truist Financial cut their price target on IQVIA from $265.00 to $261.00 and set a “buy” rating for the company in a research note on Thursday, December 12th. The Goldman Sachs Group lowered their price objective on IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. BTIG Research cut IQVIA from a “buy” rating to a “neutral” rating in a research report on Monday. Finally, Barclays lowered their price target on IQVIA from $255.00 to $235.00 and set an “overweight” rating on the stock in a report on Monday. Five analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $254.53.

IQVIA Price Performance

NYSE:IQV opened at $209.76 on Friday. The firm has a market capitalization of $38.07 billion, a price-to-earnings ratio of 27.53, a PEG ratio of 2.15 and a beta of 1.48. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. The business has a 50 day simple moving average of $200.36 and a 200-day simple moving average of $219.87. IQVIA Holdings Inc. has a 1 year low of $187.62 and a 1 year high of $261.73.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 9.17% and a return on equity of 28.17%. Equities analysts forecast that IQVIA Holdings Inc. will post 10.18 EPS for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.